Procalcitonin Level is Correlated with Community Pneumonia Severity
DOI:
https://doi.org/10.55175/cdk.v50i9.718Kata Kunci:
Pneumonia community, procalcitonin, prognosis, PSI scoreAbstrak
Procalcitonin (PCT) is a peptide consisting of 116 amino acids released by thyroid C cells in very low concentrations (<0.05 ng/mL). Microbial infection will increase the expression of CALC - 1 gene causing release of PCT from cells. A cross-sectional research was done on 60 patients with community pneumonia (July 2011 to June 2013) in Department of Internal Medicine, H.Adam Malik Hospital, Medan, consist of 33 men, 27 women, age 52.47±13.31 years. The objective is to determine the correlation between procalcitonin levels and severity of community pneumonia. The results were the percentage of PCT class I 18.3%, class II 8.3%, class III 16.7%, and class IV 56.7%; 41.7% have PSI scores ≤90, which are 25% have PSI score 91-130 and 33.3% have PSI score >130. There is a statistically significant correlation between PCT levels and severity of community pneumonia (p =0.0001 somers’d test)
Prokalsitonin adalah prohormon kalsitonin, berupa peptida 116 asam amino yang dilepaskan oleh sel C tiroid dalam keadaan normal dan konsentrasinya sangat rendah (<0,05 ng/mL). Infeksi mikroba akan meningkatkan ekspresi gen CALC-I yang menyebabkan lepasnya PCT dari sel. Penelitian observasional dengan metode cross-sectional dilaksanakan pada 60 pasien pneumonia komunitas rawat inap (Juli 2011 s/d Juni 2013) di Departemen Ilmu Penyakit Dalam RS H. Adam Malik Medan, terdiri dari 33 pria dan 27 wanita dengan usia rata-rata 52,47±13,31 tahun. Tujuan penelitian untuk mengetahui hubungan kadar prokalsitonin terhadap derajat dan beratnya pneumonia komunitas. Hasil penelitian menunjukkan bahwa persentase pasien dengan kadar PCT derajat I 18,3%, derajat II 8,3%, derajat III 16,7%, dan derajat IV 56,7%; pada 41,7% pasien dijumpai skor PSI (Pneumonia Severity Index) ≤90, 25% pasien dengan skor PSI 91-130 dan 33,3% pasien dengan skor PSI >130. Terdapat hubungan signifikan antara derajat skor PSI dan peningkatan kadar PCT (uji korelasi Somers’d p=0,0001).
Unduhan
Referensi
Summary Executive. Pola penyakit penyebab kematian di Indonesia. Survei Kesehatan Rumah Tangga (SKRT). Jakarta; 2001 .p. 2.
Dahlan Z. Pandangan baru pneumonia atipik dan terapinya. CDK. 2000;128:6.
De Frances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National hospital discharge survey. National Health Statistic Reports. 2008;5:1-20
Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, et al. Risk prediction with procalcitonin and clinical rules in community acquired pneumonia. Ann Emerg Med. 2008;52(1):48-58.
Mira JP, Max A, Burgel PR. The role of biomarker in community acquired pneumonia: Predicting mortality and response to adjunctive therapy. Crit Care. 2008;12(suppl 6):1-7.
Masia M, Gutierrez F, Shum C, Padilla S, Navarro JC, Flores E, et al. Usefulness of procalcitonin level in community acquired pneumonia according to patients outcome research team pneumonia severity index. Chest. 2005; 128:23-9.
Summah H, Qu JM. Biomarkers: A defenite plus in pneumonia. Mediators Inflamm. 2009;2009:675753. doi: 10.1155/2009/675753.
Crain C. Procalcitonin. Department of Anaesthetics. University of Kwazulu-Natal; 2010 .p. 3–24.
Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et.al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community acquired pneumonia. BMC Infect Dis. 2007;7:1- 10.
Christ-Crain M, Stolz D, Bingisser R, Mueller C, Mledinger D, Huber P, et.al. Procalcitonin guidance of antibiotics therapy in community acquired pneumonia. Am J Respir Crit Care Med. 2006;174:84 -93.
Christ-Crain M, Opal SM. Clinical review: The role of biomarkers in the diagnosis and management of community acquired pneumonia. Critical care. 2010;14:1-11.
Kruger S, Ewig S, Marne R, Papassotisiou J, Richter K, Von Baum H, et.al. Procalcitonin predicts patient at low risk of death from community acquired pneumonia across all CRB-65 Classes. Eur Respir J. 2008;31:349-55.
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):27-72.
Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011;66(Suppl 2):33- 40.
Okimoto N, Hayashi Y, Ishiga M, Nanba F, Kishimoto M, Yagi S, et al. Procalcitonin and severity of community-acquired pneumonia. J Infect Chemother. 2009;15(6):426-7.
Lee M, Snyder A. The role of procalcitonin in community acquired pneumonia: A literature review. Adv Emerg Nurs J. 2012;34(3):259-71.
Kim JH, Seo JW, Mok JH, Kim MH, Cho WH, Lee K, et al. Usefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumonia. Tuberc Respir Dis (Seoul) 2013;74(5):207-14.
Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006;32(3):469-72
Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10(3):96.
Abula A, Wang Y, Ma L, Yu X. The application value of the procalcitonin clearance rate on therapeutic effect and prognosis of ventilator associated pneumonia. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2014;26(11):780-4.
Abdelsadek A, Naga OA, Shams MA, Eltelbany E, Hamd A. Procalcitonin as a predictor for severity and etiology of community acquired pneumonia (CAP). Br J Med Med Res. 2017;19(1): 1-8
Singanayagam, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia: A review. Q J Med 2009;102:379–88.
Dahlan Z. Pneumonia. In: Sudoyo AW, Setyohadi B, Alwi I, Simadibrata M, Setiati S, editors. Buku ajar ilmu penyakit dalam. Jilid III. Internal Publ.; 2009 .p. 2196-206.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.